Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$8.5MCash on Hand
8.6mo Cash Runway
Follow TOVX by emailGet an email when TOVX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TOVX, unsubscribe in one click. Privacy
📣 What TOVX Says Is Next
fourth quarter of this year · ““Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”
Company press release, Nov 12, 2026 · SEC filing
second half of 2026 · “Results from the VIRAGE2 study will inform the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial. o VIRAGE2 is expected to complete enrollment during the second half of 2026, and initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027.”
Company press release, Aug 11, 2026 · SEC filing
H2 2026 · “Enrollment into the VIRAGE2 trial is expected to be completed in H2 2026 and initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Theriva reported Q3 2026 results: G&A fell to $923,000 from $1.9 million and R&D fell to $612,000 from $2.6 million. Cash was $8.5 million with runway into Q1 2027. It sold its SYN-004 enzyme portfolio to Biossil Labs for $350,000 upfront plus milestones. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 2, 2026 ·
Deal Theriva sold its SYN-004 (ribaxamase), SYN-007 and SYN-006 assets to Biossil Labs for a $350,000 upfront payment, with up to $3 million in regulatory milestones, up to $88 million in sales milestones, and low single-digit royalties capped at $250 million. Biossil assumes development and commercialization costs. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Shareholder vote Theriva Biologics will hold a special stockholder meeting on November 18, 2026 to vote on raising authorized common stock to 500,000,000 shares, ratifying approval for issuing up to 16,184,560 shares on warrant exercise, and possibly adjourning the meeting. Form DEF 14A · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 results: first patients dosed in the VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC. Cash and cash equivalents were $11.3 million as of June 30, 2026, with runway into Q1 2027. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2027 · Phase 1/2 · Recruiting · A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer Registry primary completion date, not a results date
Sep 2029 · Phase 1/2 · Active Trial · SYN-004 Safety and Tolerability in Allo-HCT Subjects Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not TOVX's own candidates): Lovastatin, Gemcitabine Hydrochloride, Paclitaxel, Durvalumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TOVX holds $8.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $3M/quarter from operations,
an estimated runway of 8.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:84 · High
Cash runway 9 months +30
ATM program on file since Oct 2025 +15
Shelf registration (S-3, May 2024) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TOVX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.